Business
Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results
Revenue of $274.1 million in Q2, ahead of outlookDiluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09Repurchased approximately 1.1 million shares opportunistically in Q2Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and fi
About this update from Prestige Consumer Healthcare Inc.
[{"type":"image","alt":"Prestige Consumer Healthcare Inc.","displaySize":"","headline":null,"caption":"Prestige Consumer Healthcare Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FLwmlDskH0PHRRLgz3xb6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $274.1 million in Q2, ahead of outlook","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Diluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Repurchased approximately 1.1 million shares opportunistically in Q2","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":341,"olType":false},{"type":"text","content":"TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2025.","length":198,"tagName":"p"},{"type":"text","content":"“Our second quarter results surpassed our sales and earnings expectations helped primarily by Clear Eyes® supply timing and the timing of certain retailer orders. We remain pleased with the performance of the remainder of our business, where we continue to focus on brand-building behind our diverse portfolio of leading brands and maintaining our leading financial profile. This proven formula continues to generate robust free cash flow, which enabled us to repurchase over one million in shares during the second quarter to further enhance shareholder value,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.","length":638,"tagName":"p"},{"type":"text","content":"Second Fiscal Quarter Ended September 30, 2025","length":46,"tagName":"p"},{"type":"text","content":"Reported revenues in the second quarter of fiscal 2026 of $274.1 millio...